Diagnosis and management of primary hyperparathyroidism: recommendations from the Bone Section of the Hellenic Endocrine Society

Ethical approval

Not applicable for this article.

Informed consent

Not applicable for this article.

Conflict of interest in respect to the article

ADA reports fees for lectures/advisory boards from Amgen, Bianex, Eli-Lilly, Er-Kim, Galenica, ITF, Uni-pharma, and UCB; MPY reports fees for lectures/advisory boards from Amgen, Er-Kim, Galenica, Genesis, and UCB; EK reports fees for lectures/advisory boards from Amgen, AstraZeneca, Er-Kim, and UCB; FA reports fees for lectures/advisory boards from Amgen, Er-Kim, and Kyowa Kirin; AV has nothing to declare; ST reports fees for lectures/advisory boards from Amgen, AstraZeneca, Elpen, Er-Kim, Genesis and UCB; PM reports research grants from Amgen and Galenica and fees for lectures/advisory boards from UCB, Elpen, Bianex, Eli-Lilly.

Comments (0)

No login
gif